With antimicrobial resistance threatening additional future healthcare costs of $1 trillion, better data would help shore up national action plans.
Health systems around the world must secure equitable access to anti-obesity drugs and ensure they are used in tandem with wider public-health programmes.
More investment is needed in clinical research if Africa is to manage the double disease burden of infectious diseases and non-communicable conditions.
Antimicrobial resistance is known as a quiet pandemic but more data, investment, policy incentives and a holistic approach via One Health could defeat it.
